These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12508935)

  • 1. Raloxifene and pituitary secretion in post-menopausal women.
    Lasco A; Cannavò S; Gaudio A; Morabito N; Trifiletti A; Di Cesare E; Basile G; Nicita-Mauro V; Frisina N
    J Endocrinol Invest; 2002; 25(10 Suppl):95-6. PubMed ID: 12508935
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women.
    Cheng WC; Yen ML; Hsu SH; Chen KH; Tsai KS
    Endocrine; 2004; 23(2-3):215-8. PubMed ID: 15146102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenal function under long-term raloxifene administration.
    Genazzani AR; Lombardi I; Borgioli G; di Bono I; Casarosa E; Gambacciani M; Palumbo M; Genazzani AD; Luisi M
    Gynecol Endocrinol; 2003 Apr; 17(2):159-68. PubMed ID: 12737677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women.
    Vogelvang TE; Mijatovic V; Kenemans P; Schalkwijk CG; van der Mooren MJ
    Am J Cardiol; 2004 Nov; 94(9):1205-8. PubMed ID: 15518626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of clomiphene and raloxifene on gonadotrophin secretion in postmenopausal women: evidence of nongenomic action.
    Garas A; Trypsianis G; Kallitsaris A; Milingos S; Messinis IE
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):256-62. PubMed ID: 15272923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
    Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
    Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
    O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
    Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses.
    Carranza-Lira S; Gooch AL; Saldivar N; Osterwalder MS
    Int J Fertil Womens Med; 2007; 52(2-3):93-6. PubMed ID: 18320867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia.
    Tsourdi E; Kourtis A; Farmakiotis D; Katsikis I; Salmas M; Panidis D
    Fertil Steril; 2009 Apr; 91(4 Suppl):1427-30. PubMed ID: 18692782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raloxifene: is it really effective on mood changes in postmenopausal osteopenic women?
    Karsidag AY; Karsidag C; Buyukbayrak EE; Kars B; Pirimoglu M; Unal O; Turan MC
    J Psychosom Obstet Gynaecol; 2010 Dec; 31(4):273-8. PubMed ID: 20961269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic dosages of raloxifene do not modify myeloperoxidase and F2alpha-isoprostane levels in postmenopausal women.
    Oviedo PJ; Hermenegildo C; Tarín JJ; Cano A
    Fertil Steril; 2005 Dec; 84(6):1789-92. PubMed ID: 16359994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of raloxifene -- a selective oestrogen receptor modulator -- on kidney function in post-menopausal women with Type 2 diabetes: results from a randomized, placebo-controlled pilot trial.
    Hadjadj S; Gourdy P; Zaoui P; Guerci B; Roudaut N; Gautier JF; Chabin M; Mauco G; Ragot S;
    Diabet Med; 2007 Aug; 24(8):906-10. PubMed ID: 17451421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mood modifications with raloxifene and continuous combined estrogen plus progestin hormone therapy.
    Carranza-Lira S; MacGregor-Gooch AL; Saráchaga-Osterwalder M
    Int J Fertil Womens Med; 2004; 49(3):120-2. PubMed ID: 15303313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procoagulant state after raloxifene therapy in postmenopausal women.
    Azevedo GD; Franco RF; Baggio MS; Maranhão TM; Sá MF
    Fertil Steril; 2005 Dec; 84(6):1680-4. PubMed ID: 16359964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
    Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
    Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women.
    Gardner M; Taylor A; Wei G; Calcagni A; Duncan B; Milton A
    J Clin Pharmacol; 2006 Jan; 46(1):52-8. PubMed ID: 16397284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.
    Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N
    Menopause; 2006; 13(5):787-92. PubMed ID: 16912660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].
    Urano T
    Clin Calcium; 2005 Apr; 15(4):591-5. PubMed ID: 15802770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oestrogenic effects of neonatal administration of raloxifene on hypothalamic-pituitary-gonadal axis in male and female rats.
    Pinilla L; González LC; Gaytán F; Tena-Sempere M; Aguilar E
    Reproduction; 2001 Jun; 121(6):915-24. PubMed ID: 11373178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.